Clinical data for Cell Therapy 2.0 is coming soon, with a further $75 million in financing

The company said the funds will be used to support ongoing and planned research, clinical development of products, and the establishment of a production platform for the company's proprietary, vertically integrated viral vectors and cell therapy products, and plans to advance the product to Phase 2 in 2021Tmunity was founded in 2015 with core technologies related to CAR-T and TCRAccording to public information, Tmunity is a company focused on clinical biotherapeutic drugs, dedicated to the clinical development of T-cell therapy, providing a new generation of T-cell immunotherapy for critical patients, saving patients' lives and improving their quality of lifeTo date, Tmunity has received $231 million in financingFrom the founding team, its core technology and founding team originated at the University of Pennsylvania in the United StatesIt is understood that Tmunity has an exclusive partnership and licensing agreement with the University of PennsylvaniaIn fact, the team of founders of scientists, led by DrCarl HJune, has achieved remarkable results in the field of cell and gene therapy, particularly in the field of T-cell medicine and related technologies, where it has a high reputationpart of Tmunity is working on the pipeline (Photo: Tmunity.com)In terms of research and development capabilities, Tmunity is currently developing a diverse portfolio of new treatmentsThree candidate drugs have entered the clinical stage, including CAR-T therapy for solid tumorsExisting CAR-T therapy has been shown to be effective for some blood tumors, but the difficulties of solid tumors are still being overcomeCurrently, Tmunity's first clinical program, PSMA CAR-T, is a treatment for prostate cancerThese CAR-T cells have been double-modified to target PSMA antigens on the surface of cancer cells and to reduce the immunosuppression of cancer cells by blocking TGF beta signalingthe company's other clinical project, NY-ESO-1 TCR-T Triple Knockout TCR (NYCE), edited T cells through CRISPR technologyThe modified T-cell targeting NY-ESO-1 antigen will be used to treat myeloma, melanoma and glioblastomaTmunity plans to present some of the clinical data on the therapy at the American Society of Hematology (ASH) annual meeting in December"To win the war on cancer, we need smarter weapons," said Jorge Conde, general partner at a16z, a representative of theinvestorDrCarl HJune, the founder of Tmunity, invented CAR-T, one of the most significant cancer breakthroughs in recent historyThe Tmunity team has built a ground-breaking platform that has been incorporated into human clinical trials for solid and blood tumorsThis is a 'dream team' that will realize the bold and promising dream of curing disease with engineered T-cellsReferences:s1 sTmunity Raises $75 Million in Series B Financing to Advance Next-Generation T-Cell Therapiesd November 1 2019 from https://